Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sandoz Group Ltd ( (CH:SDZ) ) has shared an update.
Sandoz has launched WYOST® and Jubbonti®, the first FDA-approved interchangeable denosumab biosimilars in the US, enhancing access for patients with osteoporosis and cancer-related skeletal events. This launch strengthens Sandoz’s US biosimilar portfolio and aligns with its growth strategy to lead the biosimilar market, offering cost-effective treatment options and comprehensive patient support.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF45.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz Group Ltd is a global leader in generic and biosimilar medicines, focusing on oncology and immunology biosimilars. The company has a strong market presence in the US, building on its established leadership in the biosimilar sector since 2015.
YTD Price Performance: 14.34%
Average Trading Volume: 1,346,798
Current Market Cap: CHF18.36B
For an in-depth examination of SDZ stock, go to TipRanks’ Stock Analysis page.